Ongoing clinical trials in diabetes at The University of Massachusetts Memorial Medical Center, The University of Massachusetts Children's Medical Center and the University of Massachusetts Medical School are focused on testing new treatment approaches designed to improve the quality of life for individuals with diabetes.
For information concerning any of these clinical trials, please contact the Clinical Trials Unit at: 508-856-2800
Open, Accruing Trials
(Trial has started! Ten subjects have been enrolled so far!)
• The purpose of this study is to grow new beta cells from the patient’s own peripheral blood stem cell lines and use them to investigate autoimmune diabetes in the humanized mouse.
New Onset Blood Samples
• Blood sample from newly diagnosed T1D patients will be collected within 1-3 months of diagnosis for systematic transcriptome analysis.
• Both pediatric and adult patients are eligible.
• A study designed to test whether the medication allopurinol can prevent or slow down kidney disease in people with Type 1 Diabetes.
• Eligible patients have history or presence of microalbuminuria or moderate macroalbuminuria, or evidence of declining kidney function.
The Natural History Study of the Development of Type 1 Diabetes
• A network dedicated to conducting diabetes prevention research and studying intervention therapies for children and adults with newly diagnosed Type 1 Diabetes.
T1D Exchange Type 1 Diabetes Network
• Clinic registry of about ~25,000 individuals diagnosed with T1D to learn more about T1D.
DCOE Potential Research Volunteer Registry
• Any patient (Type 1 or Type 2 Diabetes) interested in research can consent to this registry and sign up for a monthly research oriented newsletter (those who express interest in Diabetes/Endocrine System Research can complete a short survey on their background and relation to diabetes).
Conquering Diseases Biorepository Project
• Interested Type 1 or Type 2 Diabetes patients can consent to this project in order to donate a one-time blood sample to the biorepository.
Hepatic Dysfunction, Vitamin D Status, and Glycemic Cotrol in Diabetes
• To determine if the addition of Vitamin D to either metformin or an insulin regimen or a combination of both will improve glycemic control in patients between the ages of 10-50 years.
• Eligible patients have an HbA1c > 8%.
Boehringer Ingelheim Protocol BI 1245.87
• A study to evaluate whether the oral medication Empagliflozin can lower blood sugar.
• Eligible patients must be 10 to less than 18 years of age and have a diagnosis of Type 2 Diabetes. Patients can be treated with diet and exercise, metformin, and/or long acting insulin upon study entry.
• To see if the Investigational Product, human plasma derived alpha1-proteinase inhibitor (also known as Prolastin®-C) can help maintain glucose levels so that patients can rely less on insulin.
• Eligible patients must be between the ages of 6 and 18 years old, and have been diagnosed with Type 1 Diabetes mellitus within 90 days of enrollment.
• To compare the blood sugar lowering effect and safety of the medication Liraglutide with a placebo when it is given together with metformin alone or metformin in combination with long acting insulin treatment.
• Eligible patients must be between the ages of 10 and 17 years old and have a diagnosis of Type 2 Diabetes mellitus.
Trials Pending Activation
• The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with Type 2 Diabetes, Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).
Ongoing, Closed to Accrual Trials
T1D Exchange Ancillary Study: Residual C-Peptide in Patients with Type 1 Diabetes
• Investigates how often patients with T1D still produce at least some of their own insulin and if it is related to how long patients have had T1D or their age at diagnosis.
Get-In Touch, Livongo Health
• A study of a blood glucose meter (InTouch™ Blood Glucose Monitoring System) that automatically sends blood sugar results to the health care team to see how this may improve overall diabetes care.
• Due back in 3 month intervals for a venous HbA1c draw and/or survey.
• The purpose is to compare the cardiovascular safety of insulin degludec to that of the approved product, insulin glargine, in Type 2 Diabetes patients who are at least 50 years old and at risk for cardiovascular disease.